Levetiracetam 1a Farma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a key role in neurotransmitter release. By modulating SV2A, the drug decreases excessive neuronal firing and reduces the likelihood of seizure propagation without directly influencing ion channels or GABA receptors.

The specific dosage of Levetiracetam 1a Farma is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions precisely.

Safety data for levetiracetam in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women. Women should discuss any concerns with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from many antiepileptics that act on ion channels or GABA pathways. It generally has fewer drug‑enzyme interactions, a favorable tolerability profile, and does not require routine blood level monitoring, making it a convenient option for many patients.

Levetiracetam 1a Farma tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original packaging, protect it from moisture, and store away from direct sunlight to maintain potency.

Levetiracetam 1a Farma is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically advised by a healthcare professional.

Serious adverse events, though rare, can include severe allergic reactions (rash, swelling, breathing difficulty), mood disturbances such as depression or suicidal thoughts, and hematologic abnormalities like low blood cell counts. Patients should seek immediate medical attention if any of these occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Patients with uncontrolled severe psychiatric disorders should use it with caution, and those with significant renal impairment may require dose adjustments under medical supervision.